Lv2
120 积分 2022-05-13 加入
Ovarian cancer
1天前
待确认
Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis
7天前
已完结
Olaparib dose reduction in BRCA-mutated platinum-sensitive ovarian cancer recurrence: real-world data
11天前
已关闭
First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter study
11天前
已完结
KELIM score: A marker of chemosensitivity in ovarian cancer
1个月前
已关闭
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
1个月前
已完结
Bystander effect of antibody–drug conjugates: fact or fiction?
1个月前
已完结
Downregulation of MHC-I on Melanoma Cells and Decreased CD8+ T-Cell Infiltration Are Associated With Metastatic Spread and Resistance to Immunotherapy
1个月前
已关闭
Sacituzumab govitecan in Chinese patients with recurrent/metastatic cervical cancer: Results from the phase 2 EVER-132-003 basket study (NCT05119907)
1个月前
已完结
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
2个月前
已完结
皖公网安备34019202002308
